Azilsartan medoxomil/chlortalidone - Takeda

Drug Profile

Azilsartan medoxomil/chlortalidone - Takeda

Alternative Names: Chlortalidone/azilisartan medoxomil; EdarbiClo; Edarbyclor; TAK-491/chlorthalidone; TAK-491CLD

Latest Information Update: 26 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Developer Synokem Pharmaceuticals; Takeda
  • Class Antihypertensives; Benzimidazoles; Small molecules; Sulfonamides
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Thiazide-like diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 14 Sep 2017 Launched for Hypertension in Russia (PO) before September 2017 (Takeda Russia-CIS website, September 2017)
  • 14 Sep 2017 No recent reports on development identified - Registered for Hypertension in Brazil (PO)
  • 17 Aug 2017 Azilsartan medoxomil/chlorthalidone market licensed to Hikma Pharmaceuticals in Middle East and North Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top